Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Detalles Bibliográficos
Autores principales: Gäckler, Anja, Schönermarck, Ulf, Dobronravov, Vladimir, La Manna, Gaetano, Denker, Andrew, Liu, Peng, Vinogradova, Maria, Yoon, Sung-Soo, Praga, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856751/
https://www.ncbi.nlm.nih.gov/pubmed/33530925
http://dx.doi.org/10.1186/s12882-021-02242-z
Descripción
Sumario:

Ejemplares similares